Your micro and small cap stock experts

Contact Learn More

INCANNEX HEALTHCARE LIMITED (IXHL) LISTS ON THE NASDAQ

 

Incannex rings the closing bell

INVESTORS

Canary Capital offers high conviction private placements in micro and small Cap companies to Sophisticated and Experienced investors. We also offer all investors access to IPOs and general share trading services.

Learn More

CORPORATES

Capital raising and boutique corporate advisory services for early stage and emerging companies. We fund all business growth stages from Angel and Venture Capital to IPOs and private placements.

Learn More

IN THE NEWS

ReNerve Ltd

Peripheral nerves and the repair of nerve injuries

ReNerve is developing a portfolio of tissue-based nerve repair products that are designed to be cleaner and safer than current alternatives. The products being developed by ReNerve are targeting the repair and/or replacement of peripheral nerves that have been injured following trauma, malignancy or surgery targeting better outcomes for patients.

ReNerve has 3 products in development. The most advanced product is the NerveAlign Nerve Cuff. It protects nerves and promotes regeneration and incorporates eCOO technology and has recently been approved by the USA FDA. The second product in development is the NerveAlign Nerve Graft. It is an off the shelf nerve graft for the replacement of damaged nerves without surgeons having to harvest nerves. The third product in development is the NerveAlign Bionic. This product combines Nerve Graft with Ionic Polymers that repair large sections of damages nerves.

IN THE SPOTLIGHT

HTG – RIS – Remote Inspection System

Live real-time decision making

Harvest Technology Group’s Remote Inspection System (RIS) has been launched into the global market. The software allows reliable and secure livestreaming of high-definition video and data from anywhere in the world to manage organisations’ equipment, people, and processes remotely. The software cuts data usage on existing networks by up to 80%, eliminate bottlenecks, increases safety, and innovates in ways that will transform the way business is run whilst delivering operational cost savings of up to 50%. RIS will continue to work even on the most congested and unreliable networks meaning it can be deployed anywhere, including the most challenging locations on the planet.

 

GET INSIGHTS

Sign up and get our latest insights to help with your wealth success.

  • This field is for validation purposes and should be left unchanged.

WHY CHOOSE US

Wealth of experience in the equity capital markets

Our founders have a wealth of experience in the equity capital markets and a track record of delivering superior investor returns. The key to our outperformance is our thorough due diligence when selecting opportunities as well as our willingness to work with management to help them achieve long term success.

Specialists in micro and small cap stocks

We are specialists in micro and small cap stocks across multiple industries. We work with a range of select brokers and institutions in all major Australian capital cities. Family offices, micro cap and small cap fund managers also directly invest in our opportunities.

Invest in high quality emerging Australian companies

We only invest in businesses which we believe are high quality emerging Australian companies. We work with management who are experienced leaders in their field and have a track record of delivering value for shareholders. Once funded, we monitor these businesses and work with them to help ensure they stay on course.

Meet Our Team

WHAT OUR CLIENTS SAY

Canary Capital is a vital and trusted partner for Nyrada (ASX:NYR) and they share our vision for advancing healthcare. The team at Canary Capital demonstrates a thorough approach to understanding, assessing, and selecting partners, and we have been impressed by the level of service and support they offer our business, as well as by how much they value their clients. The Canary team is always looking for ways in which they can assist Nyrada in promoting the company to investors and raising knowledge and understanding of our drug development programs.

James BonnarCEO, Nyrada Inc

I have dealt with Canary Capital since its inception and their knowledge and understanding of the microcap space is second to none. We have participated in numerous deals introduced by Canary that have done spectacularly well.

Andre MarschkeDirector, Scintilla Funds Management

Canary Capital are a pleasure to deal with and are always transparent, clear with their communication. The strategic investment approach has delivered exceptional results and positions in businesses with strong foundations for the future. We trust their judgment and advice and with very high confidence highly recommend their services.

Antonio M

I am delighted to be able to provide a reference for Canary Capital and in doing so Arun and Paul.

I have been with Canary from the beginning of the Canary journey. The sole focus of Paul and Arun is wealth creation for their clients whilst in parallel delivering successful solutions for the companies they work with.

Canary (Arun and Paul) truly value their client relationships; they invest alongside clients and I have always found them highly ethical and extremely responsive in their availability for discussion on my specific investments all whilst providing an excellent level of overall communication on broader client portfolio information that is relevant to the companies they are supporting.

Their prior and ongoing success is a testament to their skill, work ethic and perseverance in identifying undervalued companies and helping same become valuable companies whilst taking their clients along on that value-add journey.

I have no hesitation in recommending Canary Capital as a partner in any wealth journey.

Paul M

From the beginning, Canary Capital have been avid supporters of our vision and our management team. As a start-up, there were a number of hurdles we had to overcome in our first year and it has been humbling to have the unerring support of Canary every step of the way. They have maintained ongoing communications with us, offering sound advice and professional expertise when we need it. In particular, Paul and Arun’s positive endorsement with investors has been important to the success of our business thus far.

Ian OlsonCo-Founder and MD, Pointerra Limited

From the beginning, Canary Capital has been avid supporters of our vision and our management team. As a start-up, there were a number of hurdles we had to overcome in our first year and it has been humbling to have the unerring support of Canary every step of the way. They have maintained ongoing communications with us, offering sound advice and professional expertise when we need it. In particular, Paul and Arun’s positive endorsement with investors has been important to the success of our business thus far.

Paul GuilfoyleMD, Harvest Technology Group

I’ve been with Canary from the beginning. Their sole focus is wealth creation for their clients and success for the companies they work with.

Canary value their relationships, they invest alongside the client , on an ethical and communication level I’ve found them flawless.

Their outstanding success is a testament to their skill ,hard work and perseverance in identifying undervalued companies and helping them become valuable ones

Michael M

Canary Capital has worked with Exopharm (ASX:EX1) over the past 2 years – and particularly over the past 12 months. Over that time, Canary Capital has provided us a range of services and outcomes, all at the highest professional standard. My experience with Canary Capital has been very positive and they have demonstrated capabilities that match their promises time after time. As Exopharm evolves and grows, Canary Capital continues to provide important support and advice that we can rely upon and trust.

Ian DixonFounder and MD, Exopharm Limited

When raising money to grow your company it is critical to have a partner that understands your vision and that all money is not equal. Working with Paul and Arun from the Canary team to raise funds and accelerate our growth has been a fundamental part of our success at DekkoSecure

Jacqui NelsonCEO, DekkoSecure

K2fly has been involved with Canary Capital since 2017 and is delighted to recommend them as a trusted partner. On a personal level, I have benefitted greatly from their support, advice, and guidance in the last 4 years. They have helped establish K2fly as a significant Australian IT company on the ASX and they have worked tirelessly to promote the company to a wide range of investors.

Brian MillerCEO K2fly Limited

LATEST NEWS

View All Articles

Follow Us

View More

Incannex (#ASX: $IHL) meets with US FDA on development of IHL-42X to treat obstructive sleep apnoea
https://smallcaps.com.au/incannex-meets-us-fda-ihl-42x-treat-obstructive-sleep-apnoea/ @ASX_IHL

$IHL $IXHL #incannex announcement: IHL-216A observed to have a neuroprotective effect in rodent model of sports concussion; rapidly restores spatial memory post-concussion.

Read here: https://www.asx.com.au/asxpdf/20220510/pdf/458vm1xf226x2t.pdf

#asx #nasdaq #cbd #biotech

$IHL (#ASX) $IXHL Incannex Healthcare
@stockhead media article: "#Incannex had a busy quarter of clinical research breakthroughs, listing on #NASDAQ and making a play for a #cannabinoid development company with a big patent portfolio.

https://stockhead.com.au/health/with-40m-in-the-bank-and-an-exciting-product-suite-incannex-targets-game-changing-us-acquisition-for-even-more-growth/

GET INVESTMENT OPPORTUNITIES OR
RAISE CAPITAL

Contact Us